Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tonabersat SCHEMBL29377931 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Tonabersat SCHEMBL29373962 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Tonabersat SCHEMBL7169677 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Tonabersat SCHEMBL5917016 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Tonabersat SCHEMBL29717099 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Tonabersat SCHEMBL29370960 | 0.93 | ABCC9 (0.54) | ABCC9 | |
| Tonabersat SCHEMBL15973365 | 0.93 | ABCC9 (0.54) | ABCC9 | |
| SCHEMBL7044135 | 0.89 | ABCC9 (0.59) | ABCC9 | |
| SCHEMBL15546692 | 0.88 | ABCC9 (0.48) | ABCC9 | |
| SCHEMBL15546693 | 0.88 | ABCC9 (0.48) | ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | claimed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025043297-A1 | METHOD OF TREATING MYOPIA | MCFADDEN SALLY (AU) | 2025-03-06 | — | — | WO | claimed |
| US-12226393-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-18 | — | — | US | claimed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | claimed |
| CN-119300817-A | Compositions and methods for modulating epithelial-mesenchymal transition | 奥克兰联合服务有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| WO-2024187046-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | AMBER OPHTHALMICS, INC. (US) | 2024-09-12 | — | — | WO | claimed |
| JP-2011507800-A | — | — | 2011-03-10 | — | — | JP | claimed |
| EP-2254577-A1 | AMPA RECEPTOR ANTAGONISTS FOR EPILEPSY, MENTAL DISORDERS OR DEFICITS IN SENSORY ORGAN | Eisai R&D Management Co., Ltd. (JP) | 2010-12-01 | — | — | EP | claimed |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-25 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009147441-A2 | NOVEL TREATMENTS | MINSTER RESEARCH LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| WO-2009147442-A1 | NOVEL TREATMENTS | MINSTER RESEARCH LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| WO-2009082039-A1 | AMPA RECEPTOR ANTAGONISTS FOR EPILEPSY, MENTAL DISORDERS OR DEFICITS IN SENSORY ORGAN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | ABCC9 98/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | ABCC9 270/4885 |
| US-12226393-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | NLN, SMN1; SMN2, SOD1 | ABCC9 381/4885 |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | GRIK5, GRIK4, GRIK1 | ABCC9 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.